FDA Approves KAZANO — Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc.-sponsored KAZANO (alogliptin and metformin hydrochloride) tablets, an oral antidiabetic drug, received U.S. approval on January 25, 2013. This launch presents Takeda with an opportunity to bolster its diabetes portfolio and compete in the high-growth, oral combination therapy market.